JP6445434B2 - スーパーカインおよびシンセカイン：新規かつ増強されたシグナル伝達活性を有する再利用されるサイトカイン - Google Patents

スーパーカインおよびシンセカイン：新規かつ増強されたシグナル伝達活性を有する再利用されるサイトカイン Download PDF

Info

Publication number
JP6445434B2
JP6445434B2 JP2015526711A JP2015526711A JP6445434B2 JP 6445434 B2 JP6445434 B2 JP 6445434B2 JP 2015526711 A JP2015526711 A JP 2015526711A JP 2015526711 A JP2015526711 A JP 2015526711A JP 6445434 B2 JP6445434 B2 JP 6445434B2
Authority
JP
Japan
Prior art keywords
receptor
shared
cells
mutein
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015526711A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015525574A (ja
JP2015525574A5 (cg-RX-API-DMAC7.html
Inventor
ガルシア，クリストファー，ケー．
ベイツ，ダレン，エル．
モラガ，イグナシオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2015525574A publication Critical patent/JP2015525574A/ja
Publication of JP2015525574A5 publication Critical patent/JP2015525574A5/ja
Application granted granted Critical
Publication of JP6445434B2 publication Critical patent/JP6445434B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015526711A 2012-08-09 2013-08-08 スーパーカインおよびシンセカイン：新規かつ増強されたシグナル伝達活性を有する再利用されるサイトカイン Active JP6445434B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261681490P 2012-08-09 2012-08-09
US61/681,490 2012-08-09
US201261725791P 2012-11-13 2012-11-13
US61/725,791 2012-11-13
US201361825980P 2013-05-21 2013-05-21
US61/825,980 2013-05-21
PCT/US2013/054164 WO2014074186A2 (en) 2012-08-09 2013-08-08 Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018118931A Division JP2018161143A (ja) 2012-08-09 2018-06-22 スーパーカインおよびシンセカイン：新規かつ増強されたシグナル伝達活性を有する再利用されるサイトカイン

Publications (3)

Publication Number Publication Date
JP2015525574A JP2015525574A (ja) 2015-09-07
JP2015525574A5 JP2015525574A5 (cg-RX-API-DMAC7.html) 2016-03-10
JP6445434B2 true JP6445434B2 (ja) 2018-12-26

Family

ID=50685291

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015526711A Active JP6445434B2 (ja) 2012-08-09 2013-08-08 スーパーカインおよびシンセカイン：新規かつ増強されたシグナル伝達活性を有する再利用されるサイトカイン
JP2018118931A Pending JP2018161143A (ja) 2012-08-09 2018-06-22 スーパーカインおよびシンセカイン：新規かつ増強されたシグナル伝達活性を有する再利用されるサイトカイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018118931A Pending JP2018161143A (ja) 2012-08-09 2018-06-22 スーパーカインおよびシンセカイン：新規かつ増強されたシグナル伝達活性を有する再利用されるサイトカイン

Country Status (6)

Country Link
US (3) US9738696B2 (cg-RX-API-DMAC7.html)
EP (1) EP2882449B1 (cg-RX-API-DMAC7.html)
JP (2) JP6445434B2 (cg-RX-API-DMAC7.html)
CN (2) CN110615835A (cg-RX-API-DMAC7.html)
IN (1) IN2015KN00329A (cg-RX-API-DMAC7.html)
WO (1) WO2014074186A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019531729A (ja) * 2016-09-30 2019-11-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 変異体ｉｉｉ型インターフェロン及びシンセカイン
JP2018157812A (ja) * 2017-03-23 2018-10-11 東ソー株式会社 試料中に含まれる細胞の検出方法
AU2018243536B2 (en) * 2017-03-31 2024-01-25 The Board Of Trustees Of The Leland Stanford Junior University Synthekine compositions and methods of use
ES2955511T3 (es) 2018-05-14 2023-12-04 Werewolf Therapeutics Inc Polipéptidos de interleucina 2 activables y métodos de uso de los mismos
IL278615B1 (en) 2018-05-14 2025-10-01 Werewolf Therapeutics Inc Activatable interleukin 12 polypeptides and methods of using them
EP3802579A1 (en) 2018-06-01 2021-04-14 The Board of Trustees of the Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
JP7641912B2 (ja) 2019-04-19 2025-03-07 シナーキン・ファーマ・ベスローテン・フエンノートシャップ Ｉｌ１３を含む融合タンパク質
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
EP4058471A1 (en) 2019-11-14 2022-09-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2023230163A1 (en) * 2022-05-24 2023-11-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin 4 and/or interleukin 13-based eye compositions

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07508179A (ja) 1992-08-21 1995-09-14 シェリング・コーポレーション ヒトインターロイキン−１３
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
US6335426B1 (en) * 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
US6673602B1 (en) 1999-06-11 2004-01-06 The General Hospital Corporation Herpes simplex virus amplicon vector targeting system and method of using same
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
JP4505166B2 (ja) 1999-09-09 2010-07-21 シェーリング コーポレイション 哺乳動物インターロイキン−１２ｐ４０およびインターロイキンｂ３０、その組成物、抗体、薬学的組成物における使用
EP1222212A4 (en) 1999-10-06 2005-05-04 Penn State Res Found MUTANTS OF IL-13
WO2001034645A2 (en) 1999-11-11 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Mutated il-13 molecules and their uses
GB0004016D0 (en) 2000-02-22 2000-04-12 Royal Brompton Hospital Biological material and uses thereof
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
EP1315742B1 (en) 2000-08-30 2010-06-30 The Penn State Research Foundation Amino acid substitution mutants of interleukin 13
AU2002224408B2 (en) 2000-10-18 2007-08-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US20030013851A1 (en) 2001-06-07 2003-01-16 Robert Powers Solution structure of IL-13 and uses thereof
US20040248260A1 (en) 2001-10-26 2004-12-09 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
CA2593648A1 (en) 2005-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
US20100317577A1 (en) 2005-09-09 2010-12-16 Department Of Health And Human Services Methods and Compositions for Inhibiting Cell Death or Enhacing Cell Proliferation
WO2007048019A2 (en) 2005-10-20 2007-04-26 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
WO2007146046A2 (en) 2006-06-07 2007-12-21 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
WO2008101671A2 (en) 2007-02-19 2008-08-28 Apogenix Gmbh Il-4 fc fusion proteins
JP2010536386A (ja) 2007-08-24 2010-12-02 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 受容体標的化試薬
CN104045716A (zh) 2008-05-16 2014-09-17 拜耳医药保健有限公司 靶向性凝固因子及其使用方法
WO2010031185A1 (en) 2008-09-19 2010-03-25 Protox Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins
US20100183545A1 (en) 2008-10-14 2010-07-22 The United States Of America, As Represented By The Secretary, Targeted cargo protein combination therapy
JP2010154842A (ja) 2008-12-03 2010-07-15 Koji Kawakami Ｅｇｆｒを標的にした新規抗がんキメラペプチド
US20110023680A1 (en) 2009-07-30 2011-02-03 Kuo-Chung Wang Pcb cutter module with detachable cutters
TWI397428B (zh) 2009-12-29 2013-06-01 Ind Tech Res Inst 標的第四介白素受體之傳輸系統
WO2011106779A1 (en) 2010-02-26 2011-09-01 Aerovance Inc. Use of modified il-4 mutien receptor antagonists to treat dermatitis
WO2011108166A1 (ja) 2010-03-03 2011-09-09 シャープ株式会社 表示装置およびその駆動方法、ならびに液晶表示装置
EP2629788A4 (en) 2010-10-22 2014-03-19 Protox Therapeutics Corp USE OF HUMAN SERUM ALBUMIN TO REDUCE THE ANTIGENICITY OF THERAPEUTIC PROTEINS
EP2655409A4 (en) 2010-12-22 2015-07-01 Univ Leland Stanford Junior SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2
ES2649967T3 (es) 2011-04-08 2018-01-16 Baylor College Of Medicine Inversión de los efectos del microentorno tumoral utilizando receptores quiméricos de citocinas
WO2012139112A1 (en) 2011-04-08 2012-10-11 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Ubiquitin fusions for improving the efficacy of cytosolic acting targeted toxins
US9512194B2 (en) 2012-01-27 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Modified IL-13 polypeptides
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
US10106592B2 (en) 2013-09-24 2018-10-23 Medicenna Therapeutics Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
CA2930243A1 (en) 2013-11-11 2015-05-14 Wake Forest University Health Sciences Epha3 and multi-valent targeting of tumors
WO2015117229A1 (en) 2014-02-07 2015-08-13 Mcmaster University Trifunctional t cell-antigen coupler and methods and uses thereof
KR20170073593A (ko) 2014-09-09 2017-06-28 유넘 테라퓨틱스 키메라 수용체 및 면역 요법에서의 그의 용도
CN107002084B (zh) 2014-09-19 2021-09-10 希望之城公司 靶向IL13Rα2的共刺激嵌合抗原受体T细胞
SG11201704519YA (en) 2014-12-02 2017-07-28 Roger Williams Hospital Methods and compositons for treating cancer
IL260218B2 (en) 2016-01-11 2023-04-01 Novartis Ag Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins
US20200095301A1 (en) 2016-12-14 2020-03-26 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
US10849960B2 (en) 2017-09-08 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer
WO2019073299A1 (en) 2017-10-10 2019-04-18 Medicenna Therapeutics, Inc. IL-4 FUSION FORMULATIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS
CA3129200A1 (en) 2019-02-07 2020-08-13 Medicenna Therapeutics, Inc. Il-4r as a biomarker in cancer
CA3183825A1 (en) 2020-06-24 2021-12-30 Fahar Merchant Bifunctional superkines and uses thereof

Also Published As

Publication number Publication date
IN2015KN00329A (cg-RX-API-DMAC7.html) 2015-07-10
JP2018161143A (ja) 2018-10-18
JP2015525574A (ja) 2015-09-07
US20180016316A1 (en) 2018-01-18
CN110615835A (zh) 2019-12-27
WO2014074186A2 (en) 2014-05-15
US20210188932A1 (en) 2021-06-24
WO2014074186A3 (en) 2014-06-19
EP2882449B1 (en) 2019-05-15
US20160244499A1 (en) 2016-08-25
EP2882449A2 (en) 2015-06-17
EP2882449A4 (en) 2016-03-09
US12187771B2 (en) 2025-01-07
US10738096B2 (en) 2020-08-11
US9738696B2 (en) 2017-08-22
CN104619334A (zh) 2015-05-13

Similar Documents

Publication Publication Date Title
JP6445434B2 (ja) スーパーカインおよびシンセカイン：新規かつ増強されたシグナル伝達活性を有する再利用されるサイトカイン
JP7729570B2 (ja) インターロイキン－２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
JP6441867B2 (ja) インターロイキン２のスーパーアゴニストおよびアンタゴニスト
Udalova et al. Macrophage heterogeneity in the context of rheumatoid arthritis
TWI357336B (en) Uses of il-23 agonists and antagonists; related re
CN112843222A (zh) Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用
US20110311475A1 (en) Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants
CN103382220A (zh) 具有抗感染、抗肿瘤活性的细胞因子fam19a4及其应用
CA2946398C (en) Superagonists, partial agonists and antagonists of interleukin-2
CN116854821A (zh) IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途
Munker et al. Molecular Biology and Cytokines

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171004

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180622

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181023

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181129

R150 Certificate of patent or registration of utility model

Ref document number: 6445434

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250